This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): naltrexone hydrochloride
Description: REVIA is a pure opioid antagonist that blocks the effects of opioids by competitive binding at opioid receptors. The mechanism of action of REVIA in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data.
Deal Structure: In December 2008, Teva closed its acquisition of Barr.
Pink Sheet In Brief: DuPont Merck's ReVia
Additional information available to subscribers only: